Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Mandates Monthly Safety Summaries For Approved COVID-19 Vaccines

Executive Summary

EU regulators have agreed on supplementary pharmacovigilance requirements applicable to COVID-19 vaccines following approval.

You may also be interested in...



Moderna Lauds Joint Work With Health Authorities On Spikevax Safety Monitoring

A senior executive at Moderna recounts how the company used a variety of data sources to identify potential safety signals for its Spikevax COVID-19 vaccine during a state of “hyper-pharmacovigilance.”

Norway COVID-19 Vaccine Deaths Draw Global Attention

Reports from Norway about deaths in very frail, elderly patients soon after receiving Pfizer/BioNTech’s COVID-19 jab have drawn regulatory scrutiny. While the European Medicines Agency has launched an investigation, Australia is examining the need for specific warnings about risks of vaccination in the very frail elderly or terminally ill patients.

EMA All Set To Oversee Use Of COVID-19 Treatments, Vaccines In Clinical Practice

The European Medicines Agency has finalized infrastructure to monitor the safety and effectiveness of COVID-19 medicines and vaccines when they are used in day-to-day clinical practice following marketing authorization.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel